The rates of survival and disease recurrence improved significantly when a personalized mRNA vaccine tailored to the patients’ tumor genetics was coupled with immunotherapy in those who had undergone surgery for high-risk melanoma, according to novel findings presented by Khattak et al at the 2023 ASCO Annual Meeting (Abstract LBA9503).
2023
Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma
Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
FDA news: License applications accepted for melanoma, endometrial cancer therapies
The FDA announced several regulatory actions the past few weeks.
Navitoclax Plus Dabrafenib and Trametinib Shows Activity in BRAF-Mutant Melanoma
Combination treatment with dabrafenib, trametinib, and navitoclax has demonstrated activity in patients with BRAFV600-mutant, advanced melanoma, according to research presented at the ASCO Annual Meeting 2023.